Observational studyBMC cancer2021

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

Mariano Provencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.